Sort
48,018 grants matching “immunotherapy”
Novel Potent Autophagy Inhibitors for Melanoma
$456,253Jeffrey D Winkler · Wistar Institute · P01 · FY2015 · CA
Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
$456,195Ya-Chen Tina Shih · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · HS
Immunization to Block the Effects of Nicotine
$456,156Paul Pentel · Hennepin Healthcare Research Institute · R01 · FY2009 · DA
Sublingual Supramolecular Vaccines and Immunotherapies
$456,143Joel H Collier · Duke University · R01 · FY2024 · AI
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy
$456,124Li Ma · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Enhanced imaging and treatment of aggressive subtypes of prostate cancer
$456,081Martin G Pomper · Johns Hopkins University · R01 · FY2023 · CA
Laboratory and Clinical studies on T-cells recognizing NSCLC
$456,056James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Central mechanisms of glucocorticoid circadian rhythm dysfunction in breast cancer
$456,048Jeremy Borniger · Cold Spring Harbor Laboratory · R01 · FY2024 · CA
TWO Compartment Models to Improve Brain Tumor Therapy
$456,020Edward A Neuwelt · Oregon Health & Science University · R01 · FY2006 · NS
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
$456,006Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2015 · CA
Novel Potent Autophagy Inhibitors for Melanoma
$455,948Jeffrey D Winkler · Wistar Institute · P01 · FY2016 · CA
Enhancing ultra-sound-mediated tumor ablation with phase-shift nanoemulation
$455,924Tyrone Porter · Boston University (Charles River Campus) · R01 · FY2016 · EB
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
$455,893Jelani Chinelo Zarif · Johns Hopkins University · R01 · FY2025 · CA
Novel Potent Autophagy Inhibitors for Melanoma
$455,888Jeffrey D Winkler · Wistar Institute · P01 · FY2017 · CA
Defining epigenetic signaling to reshape pancreatic tumor microenvironment
$455,853Jiaqi Shi · University Of Michigan At Ann Arbor · R37 · FY2023 · CA
Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy
$455,851Ruoning Wang · Research Inst Nationwide Children'S Hosp · R01 · FY2024 · CA
TWO Compartment Models to Improve Brain Tumor Therapy
$455,828Edward A Neuwelt · Oregon Health & Science University · R01 · FY2007 · NS
Immune Response to iPSC-Derived Beta Cells in Type 1 Diabetes
$455,801Megan Sykes · Columbia University Health Sciences · R01 · FY2017 · DK
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
$455,723Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AR
The role of IL-27/Lag3 axis in regulating Foxp3+ regulatory T cell function
$455,723Booki Min · Northwestern University At Chicago · R01 · FY2025 · AI
Human Monoclonal Antibodies against Botulinum Toxins
$455,681Scripps Research Institute · U01 · FY2005 · AI
Core B - Cell Engineering and Manufacturing Facility
$455,618Donald L Siegel · University Of Pennsylvania · P01 · FY2024 · CA
Targeting Negative Regulatory Pathways for Immunotherapy of B-Cell Lymphomas
$455,617Eduardo M Sotomayor · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
Molecular Glues to Target RAS-MAPK Driven Cancers
$455,542Arvin Dar · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Targeting HSP70 for MelanomaTherapy
$455,537Maureen E Murphy · Wistar Institute · P01 · FY2022 · CA